• Describe the immune cells and proinflammatory proteins that represent therapeutic targets in SLE including BAFF, type 1 interferon, and cytokines associated with JAK/STAT signaling
• Explain how dysregulated innate and adaptive immune responses lead to specific clinical manifestations and disease consequences in patients with SLE
• Evaluate the safety and efficacy of new and emerging SLE therapies that target its pathogenetic pathways
• Select treatments for patients with SLE based on their pathogenic rationale

This enduring TeleECHO activity will explore the use of JAK inhibitors for the management of rheumatoid arthritis (RA) through interactive case studies. Faculty will review emerging efficacy and safety data, discuss guideline recommended care of RA, and help clinicians identify candidates for treatment with JAK inhibitors.

This educational activity will explore the use of monoclonal antibodies for the treatment and prevention of COVID-19 in pediatric patients. A review of available clinical data will help clinicians identify candidates for therapy and select appropriate treatments based on the most up-to-date information.

This enduring TeleECHO educational series targets healthcare gaps related to the familiarity and understanding of CDK4/6 inhibitor clinical trial designs and results on efficacy, safety, and real-world studies, impacting outcomes through current practice patterns and treatment strategies in the management of HR+/HER2- metastatic breast cancer (mBC).

This case-based online enduring activity will cover the treatment and management of patients with Type 2 diabetes mellitus (T2D) who are at high risk for chronic kidney disease.

Oncology nurses are in an inherently valuable position to be in the frontline of breast cancer treatment for patients. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. 

This educational activity will assess the pathophysiology and disease domains of psoriatic arthritis as well as review FDA-approved agents and their roles in in treating the disease. Additionally, we will discuss the appropriateness of combination or monotherapy regimens and unanswered questions in this area.

This online activity will cover the pneumococcal vaccinations in specific populations.

This live virtual activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.

This enduring activity will help clinicians reduce the significant delay between onset of symptoms and diagnosis of axial spondyloarthritis (axSpA) by identifying patients with inflammatory back pain who should be promptly referred to a rheumatologist for further assessment. Case studies and engaging whiteboard animations on the features of axSpA and the consequences of delays in diagnosis create a memorable and practical learning experience.

Pneumococcal disease caused by Streptococcus pneumoniae is the leading cause of pneumonia-related deaths and poses an important global public health concern. There are several vaccines available for prevention of this disease, but their implementation in the clinic is challenged by complex recommendations of their administration for various patient populations and by complicated guidelines for appropriate spacing and sequencing of vaccine schedules. Managed Care Specialists need to understand the nuances of pneumococcal vaccines to guide physicians on their appropriate use to reduce infections and improve clinical outcomes, particularly for at-risk patients. This educational activity will explore the impact of pneumococcal disease, pathophysiology of disease, guidelines recommendations, and strategies for managing vaccine hesitancy. In addition to a didactic presentation, the program features animations and case discussions to highlight the different aspects of this disease.

Through a series of informative lectures and podcast interviews, this educational series will target clinicians in the field of rheumatology who have patients with psoriatic arthritis. We will provide the latest information on clinical presentation, differential diagnosis, therapeutic targets, and clinical trial data on current and emerging therapies to help learners reduce both short- and long-term consequences of the disease.

This online activity with an integrated case-based learning component will enable clinicians to recognize emerging targets in the management of anemia of chronic kidney disease (CKD) through an understanding of the underlying pathophysiology and clinical trials evaluating novel therapies. By integrating these data with the current standards of care in the management of anemia of CKD, clinicians will be better able to understand the role of multiple healthcare professionals in the management of this common complication of CKD. Additionally, the integrated case-based activity within this program will ensure that healthcare professionals can readily translate learnings to patient interactions, ensuring that patients and the healthcare team are aware fully aware of emerging therapeutic alternatives.

This enduring activity will focus on the T-cell Immunoreceptor with Ig and ITIM Domains (TIGIT).

This enduring TeleECHO program will explore the role of real-world evidence in informing management decisions of elderly and frail patients with relapsed and refractory multiple myeloma (RRMM). A brief didactic presentation will discuss prognostic features and key management considerations for the elderly and frail patient populations. A summary of clinical trial data and real world evidence to inform treatment selection in the first-line and relapse settings will also be presented. Interactive case studies will illustrate strategies for patient counseling and treatment selection in elderly and frail patients with RRMM.

This enduring activity covers the pathogenesis of Metastatic Castration-resistant Prostate Cancer (mCRPC) and which patients may benefit from using PARP Inhibitor–based Combinations.

This interactive online activity will explore the diagnosis and management of hypertrophic cardiomyopathy (HCM). A didactic presentation by expert faculty will review guideline recommendations and risk factors for complications, discuss pharmacologic and surgical treatment options, and examine clinical trial data on emerging agents. An animated case will allow learners to apply what they have learned in a simulated clinical encounter.

This CME program has been designed for endocrinologists who treat patients with type 2 diabetes. It aims to help learners evaluate the impact of weight loss and timely treatment intensification in patients with T2DM on glycemic and metabolic outcomes, and to increase knowledge of the mechanism of emerging GIP/GLP-1 receptor agonists and their impact on glycemic outcomes and body weight in order to advantageously integrate them into clinical practice when available.

This CME program has been designed to provide participants with the knowledge necessary to simultaneously address weight management and glycemic control in patients with type 2 diabetes and obesity/overweight. Participants will gain a greater understanding of guidelines-recommended pharmaceutical and lifestyle management strategies, and learn how incretin therapies with beneficial impacts on glycemic outcomes and body weight can be integrated into clinical practice. In addition to viewing a faculty presentation of relevant clinical data and guidelines, learners will participate in Med Games, an engaging gamified learning activity featuring interactive quizzes and video case studies that provide the opportunity to make decisions about patient care and get immediate feedback.

This enduring activity has been designed for HCPs treating metastatic castration-resistant prostate cancer (mCRPC) to improve: knowledge of the mechanisms of action of PARP inhibitor–based combinations for the treatment of patients with mCRPC with or without DNA damage response (DDR) alterations; awareness of new clinical data on the efficacy, safety, and tolerability of emerging PARP inhibitor–based combinations with different mechanisms of action for the treatment of patients with mCRPC; and their ability to develop individualized management plans for patients with mCRPC with or without DDR alterations that include PARP inhibitor–based combinations if appropriate.

This enduring MedGames is an interactive gamification-style CME activity that covers important topics in chronic spontaneous urticaria (CSU). The educational format of this program is engaging and covers the economic and physiological burden of CSU, diagnostic algorithms, guideline-recommended step-care management, and efficacy and safety of current and emerging biologic therapy.

In this educational activity, expert faculty will discuss the use of approved and authorized treatments for the management of patients hospitalized with COVID-19. A review of clinical trial data on the efficacy and safety of therapeutic options and strategies for selecting therapy based on disease severity and clinical factors will allow clinicians to reduce the need for invasive ventilation and improve patient outcomes.

This enduring activity will explore the diagnosis and management of NTM-LD. Whiteboard animations will identify common pitfalls that lead to delays in diagnosis and look at the mechanism of action of novel therapies for refractory disease. A case-based didactic lecture led by expert faculty will review guideline-recommended care, strategies to minimize adverse events, and clinical trial data on newer treatment options.

This case-based enduring activity will focus on the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE). Patients with EoE are often diagnosed after symptom onset, leading to greater chronic inflammation, and treatment plans are frequently not tailored to individual needs. This activity is intended to help healthcare professionals diagnose EoE earlier and provide individualized treatment based on guidelines, recent clinical data and patient characteristics.

This educational activity will review clinical trial data on the use of authorized therapies for the management of patients hospitalized with COVID-19 and explore strategies to incorporate these therapeutic options into clinical practice. This program includes a whiteboard animation on the role of inflammation in the pathophysiology of severe COVID-19 and the mechanism of action of available treatment options.

This enduring activity will cover the treatment of patients with neuromyelitis optica spectrum disorder (NMOSD).

This enduring activity is designed to review the importance of chronic kidney disease (CKD) risk reduction in patients with T2D, how to evaluate opportunities to screen for CKD risk in patients with T2D and target reductions in albuminuria, the manageability of hyperkalemia and uniqueness of novel therapy, and key takeaways and practice changes.

This enduring activity will focus on the latest updates in the optimal management of cancer-associated venous thromboembolism (VTE) based on risk stratification, clinical trial data, and appropriate guideline-informed strategies to optimize clinical outcomes. This program will inform participants of the latest best practices as recommended by professional guidelines and will equip participants to integrate multidisciplinary care and shared decision-making in practice.

This case-based enduring activity is designed to provide clinicians with an overview of Short Bowel Syndrome and highlight its impact on patient quality of life.

This educational activity will explore best practices for the management of rheumatoid arthritis (RA), axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) and juvenile idiopathic arthritis (JIA). Expert faculty will review the latest information on clinical presentation, treatment recommendations, and clinical trial data on available therapies to help learners reduce both short- and long-term consequences of disease. An innovative simulation center will allow clinicians to apply what they have learned in an interactive, animated case.

Oncology nurses are in an inherently valuable position to be in the frontline for treatment of HER2-positive solid tumors. Given identified gaps and faculty feedback, the instructional design of this program is a multi-pronged educational approach designed for an oncology nursing audience. For additional resources, please visit www.oncologynurse-ce.com.

This online activity is designed to increase HCPs recognition of metabolic pathways involved in the pathophysiology of Gaucher disease; confidence discussing clinical trial data supporting improved outcomes in Gaucher disease; understanding of the potential for treatment to modify outcomes in Gaucher disease; and understanding of shared decision-making best practices for long-term management of Gaucher disease.

This enduring activity has been designed to help dermatologists, pediatric dermatologists, primary care physicians, advanced practice providers (NPs and PAs) and other healthcare providers who are involved in the care and treatment of patients with atopic dermatitis to assess patients for physical and psychosocial burdens of AD; identify candidates for systemic therapies; better evaluate recent clinical trial data on the efficacy and safety of JAK inhibitors for the management of moderate-to-severe AD; and apply evidence-based approaches to manage moderate-to-severe AD and monitor for adverse events.

This podcast will explore the management of patients with metastatic colorectal cancer (mCRC). Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.

This enduring series will discuss the recognition and management of CKD risk in patients with T2D.

This activity discusses the growing impact of dengue fever worldwide and strategies to mitigate its spread. Featured topics of this program include signs and symptoms of dengue fever and differential diagnoses, the lifecycle of a dengue infection, and clinical trial data of approved and emerging vaccines.

This Community Whiteboard ECHO Series and Online Enduring activity is designed to increase the multi-disciplinary oncology care team recognition of the role of targeted and bispecific antibodies in management of relapsed/refractory DLBCL; strengthen their understanding of clinical trial outcomes and adverse events with targeted and bispecific antibodies; and improve their awareness of multidisciplinary best practices for managing adverse events from targeted therapies.

This activity features education regarding hormone therapy for children and adolescents with growth hormone (GH) deficiency. The program will discuss the diagnosis of GH deficiency, challenges of currently available therapies, clinical data of emerging therapies, and strategies to personalize care for childhood growth hormone deficiency (CGHD).

This case-based online activity is designed for retina specialists, ophthalmologists, primary care providers, optometrists, and other healthcare providers who manage patients with neovascular age-related macular degeneration and/or diabetic macular edema. The activity aims to improve treatment for patients who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. In addition, it will elucidate the benefits and limitations of current therapeutic approaches, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.

PODCAST ACTIVITY: These podcasts provide an up-to-date perspective on improving treatment for patients with neovascular age-related macular degeneration and/or diabetic macular edema who do not achieve optimal outcomes due to insufficient responses to therapy or insufficient adherence. This series of podcasts will elucidate the benefits and limitations of current therapeutic approaches for patients with nAMD or DME, equip participants with strategies for improving the durability of treatment response in patients receiving intravitreal therapies, and provide education on new and emerging treatment strategies.

This simulated activity depicts conversations between an oncologist, a pathologist, and a patient diagnosed with non-small cell lung cancer (NSCLC). You will watch as they engage with each other throughout the various stages of a patient’s journey, from the initial pathologic and oncologic workup at initial presentation to disease recurrence. You will participate in the simulation by answering questions throughout the activity. A brief slide presentations is available within each simulation center activity to enhance your understanding of immunological biomarkers.

This case-based virtual activity will cover the pathophysiology, clinical course, and underlying causes of NCFBE; summarize current evidence-based strategies for the diagnosis and treatment of patients with NCFBE; describe how neutrophilic inflammation and high levels of neutrophil serine proteases in patients with NCFBE provide the rationale for targeted treatment; and evaluate clinical data on therapies for NCFBE targeting neutrophilic inflammation neutrophil serine proteases.

This enduring activity has been designed to help obstetrician gynecologists and other HCPs involved in the care and treatment of patients with uterine fibroids (UF) and/or endometriosis to better support prompt initiation of treatment through early and accurate diagnosis. Key goals of this activity are to justify the need for new treatment options for patients with UFs and endometriosis based on the challenges associated with standard-of-care medical therapies and assess the results of clinical trials supporting the efficacy and safety profiles of newly approved and emerging combination therapies including GnRH antagonists for the long-term management of UFs and endometriosis. Finally, this program will outline individualized management plans for patients with UFs based on new clinical guidance & shared decision-making.

The majority of Veterans with migraine are seen in the primary care setting. Therefore, primary care professionals (PCPs) managing Veterans with migraine will need education on the most effective ways to treat it using currently available therapeutic options. This educational program seeks to effectively close those gaps.

This enduring activity will explore the management of moderate-to-severe atopic dermatitis (AD) in pediatric and adolescent patients. Innovative whiteboard animations will review the mechanism of action of systemic therapies for AD and the impact of COVID-19 on treatment selection. A review of clinical trial data, guideline recommendations, and patient-specific factors that impact management decisions will help clinicians develop personalized treatment plans and improve patient outcomes.

This initiative aims to increase the Department of Veteran’s Affairs multidisciplinary care team’s knowledge of both the efficacy and safety data from clinical trials for patients with small-cell lung cancer and review the NCCN clinical practice guidelines to optimize the outcomes of patients.

This activity provides a snapshot of the growing impact of dengue fever in Puerto Rico and strategies for prevention. Featured topics of this program include the burden of dengue fever and clinical trial data of approved and emerging vaccines.

This CME program provides a comprehensive and up-to-date perspective on the evolving management of patients with inflammatory bowel disease (IBD). We will be discussing unmet needs in the current identification and management of IBD; identifying tools to assist with differential diagnosis, clinical assessment, and selection of effective therapies for IBD; and exploring the underlying pathophysiology of IBD and the role of JAK inhibition in modifying therapeutic outcomes.

This enduring program aims to provide clinicians and patients with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for individuals with CRSwNP. Our goal is to provide information that empowers clinicians and patients to speak openly about treatment decisions and improve the standard of care for patients with this challenging disease.

This educational activity has been designed for nephrology fellows to ensure recognition of CKD risk in patients with T2D, understand novel strategies for modifying CKD risk, and review the risk of other chronic complications of T2D. We aim to evaluate current strategies for the management of CKD in T2D using novel therapeutic agents that modify long-term clinical outcomes, including third-generation mineralocorticoid antagonists; describe current disparities in CKD care in T2D and strategies for integrating novel strategies in practice, including third-generation mineralocorticoid antagonists; and lastly to summarize safety data with novel agents in the management of CKD in T2D, including best practices for managing hyperkalemia with novel mineralocorticoid antagonists.

The online activity will address the need for novel therapeutic options, including updates on advances in regenerative medicine, for patient with complex perianal fistula associated with Crohn’s disease. Learners will evaluate the current burden of perianal fistula in Crohn’s disease, pathophysiology, and the characteristics of current and emerging mechanisms of therapy.

This TeleECHO activity was designed to help oncologists and the multidisciplinary care team personalize gastric cancer treatment based on biomarker testing and use targeted therapies for HER2 positive disease treatment beyond the first line.

This online educational activity targets essential elements of the pearls of diagnosis and management of patients with α-thalassemias. Enhance your ability to evaluate the genetic and molecular pathophysiology of the various members of the α-thalassemia family and associated clinical presentations by genotype, as well as the risks for acute and chronic complications. After the timely, accurate diagnosis of α-thalassemia is made, assess the utility of traditional management strategies and the impact of emerging disease-modifying pharmacotherapy for the management of patients with α-thalassemias.

This CME program has been designed for primary care clinicians, pharmacists, and diabetes educators who care for patients with diabetes as well as patient audiences to increase knowledge of the relationship of glucose variability (GV) and time in range (TIR) to macro- and microvascular outcomes; enhance the ability to explain the importance of continuous glucose monitoring (CGM) and various CGM metrics; and select among basal insulin formulations based on their impacts on TIR and GV.

This TeleECHO series has been designed for US-based rheumatologists, nurses, and allied healthcare professionals involved in the management of patients with rheumatoid arthritis (RA), to better interpret data from clinical trials supporting the efficacy, safety, and tolerability of JAK inhibitors (JAKi) with different mechanisms of action in patients with moderate-to-severe RA. This series will help health professionals incorporate new evidence-based management recommendations on the use of JAKi for patients with moderate-to-severe RA into clinical practice, and it also supports patient-centered multidisciplinary team-based approaches to the management of those patients with moderate-to-severe RA.

RELEASED DATE: October 03, 2022
EXPIRATION DATE: October 03, 2023

This enduring activity will help health care professionals better evaluate the potential for multi-cancer early detection technologies to improve cancer detection and therapeutic outcomes in cancer care; analyze the accuracy for application of multicancer early detection technologies and ongoing trials; and choose appropriate patient populations that may be candidates for screening with multicancer early detection technologies and ensure clinicians are ready to discuss the meaning of test results with patients.

RELEASE DATE: October 05,  2022
EXPIRATION DATE: October 05, 2023

This educational activity will explore best practices to ensure prompt and accurate diagnosis of COVID-19 infection and the provision of outpatient care for patients with COVID-19 while incorporating shared decision-making principles and addressing disparities in care.

RELEASED DATE: October 06, 2022
EXPIRATION DATE: October 06, 2023

This program will discuss tumorigenesis in advanced non-small cell lung cancer (NSCLC) and the mechanism of actions of checkpoint inhibitors, the latest clinical data describing the efficacy and safety of first-line use of PD-1 inhibitor therapy, alone and in combination, and the use of immunotherapy in the first-line treatment of NSCLC with no actionable mutations.

RELEASE DATE: October 07,  2022
EXPIRATION DATE: October 07, 2023

This TeleECHO session will explore the management of patients with metastatic colorectal cancer (mCRC) through a short, didactic presentation and interactive case studies. Faculty will review strategies on personalizing the selection of treatment options based on molecular testing; and discuss the management of adverse events with targeted treatments for BRAF V600-mutant mCRC.

RELEASED DATE: October 10, 2022
EXPIRATION DATE: October 10, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

• Evaluate the panel of agents available for FH and determine their appropriateness based on type of FH, individual patient risk factors, comorbidities, and prior treatment
• Assess clinical trial evidence looking at long-standing and new therapies for the treatment of patients
  with FH
• Devise treatment plans that account for genetic aberrations impacting the activity of LDL-Rs in patients with FH

RELEASED DATE: October 13, 2022
EXPIRATION DATE: October 13, 2023

This online educational program focuses on the latest data on mealtime insulin in patients with type 2 diabetes mellitus. In this program, clinicians will address appropriate treatment intensification strategies in consideration of patient-related factors, the latest clinical data, and key parameters for monitoring clinical response to mealtime insulin. Through this program, clinicians will improve their level of comfort with initiating mealtime insulins to optimize glycemic outcomes, including in underserved populations. Innovative learning strategies will reinforce the latest best practices to support clinician and patient understanding of the latest strategies in glycemic management.

RELEASED DATE: October 14, 2022
EXPIRATION DATE: October 14, 2023

This enduring activity has been designed for healthcare professionals involved in the management of patients with psoriasis to improve knowledge of the function of TYK2 in psoriasis; awareness of clinical profiles of emerging TYK2 inhibitors; their ability to discern the potential place of TYK2 inhibitors in current treatment algorithms; and the adoption of shared decision-making with patients.

RELEASED DATE:  October 25, 2022
EXPIRATION DATE:  October 25, 2023

This activity will address the challenges faced by clinicians in managing older patients with T2DM. Participants will be equipped with an enhanced ability to apply current guideline recommendations and clinical data to management plans, personalize diabetes treatment for older adults in long-term care facilities and in the community, and gain greater knowledge of the rationale for using fixed ratio combinations of basal insulin and GLP-1 receptor agonists in older adults with T2DM.

RELEASE DATE: October 26,  2022
EXPIRATION DATE: October 26, 2023

This activity features education regarding the links between obesity and diabetes, the role of the incretin system in these metabolic disorders, and use of incretin therapies to manage diabetes-related obesity.

RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023

This enduring activity is designed to help HCPs improve their ability to evaluate the risk of pneumococcal infection from a population perspective and consider the importance of various serotypes in managing population health; assess clinical data and specific data with pneumococcal serotypes to determine treatment options in the context of guidelines; and to apply best practices in implementing pneumococcal vaccination schedules to improve health outcomes.

RELEASED DATE: October 26, 2022
EXPIRATION DATE: October 26, 2023

This enduring activity is faculty-led didactic and case-based interactive activities focusing on the management of patients with Type 2 diabetes and obesity. This CME program has been designed to help clinicians recognize overweight/obesity as an important treatment target; utilize guidelines and clinical data on the use of incretin therapies for treatment intensification; and implement shared decision making to better engage patients and personalize care.

RELEASED DATE:  October 27, 2022
EXPIRATION DATE:  October 27, 2023

This activity discusses the care of patients hospitalized with SARS-CoV-2 infection. The program will address the burden of COVID-19 in the US as well as the currently circulating strains. The program is designed to help clinicians integrate the latest treatment guidelines and management strategies for this patient population into their practice. The program will present the results of the latest clinical trials of novel therapies for COVID 19 to inform clinicians’ choice of therapy for patients hospitalized with SARS-CoV-2 to reduce the risk of mortality.

RELEASED DATE: November 1, 2022
EXPIRATION DATE: November 1, 2023

This educational activity will explore the appropriate place in the therapy paradigm for immunotherapy in patients with head and neck cancer, as well as managing adverse effects of immunotherapies.

RELEASED DATE: November 04, 2022
EXPIRATION DATE: November 04, 2023

• Summarize the relevance of molecular markers and genetic data relevant to selection of therapy in CLL or AML
• Review relevant treatment best practices in both newly diagnosed and relapsed/refractory AML in consideration of disease- and patient-specific factors to inform shared decision-making
• Evaluate potential adverse events associated CLL and AML therapies to implement appropriate monitoring and counseling

RELEASED DATE: November 4, 2022
EXPIRATION DATE: November 4, 2023

• Interpret data from landmark intensification trials for the treatment of patients with mHSPC
• Facilitate access to treatment intensification for patients with mHSPC in clinical practice
• Design individualized management plans for patients with mHSPC using evidence-based guidance, recommended sequencing strategies, and clinical decision-making tools that can enhance patient involvement

RELEASED DATE: March 16, 2023
EXPIRATION DATE: March 16, 2024

This enduring activity is designed to assess the pathophysiological mechanism that results in vasomotor symptoms (VMS) due to menopause as well as evaluate both traditional and novel therapeutic options for treatment. Effective communication strategies for patient/physician interactions and possible barriers to communication will also be discussed.

RELEASED DATE: May 30, 2024
EXPIRATION DATE: May 30, 2025

This online activity has been designed for primary care, emergency care, sports neurologists, headache neurologists, and other healthcare professionals involved in the management of people with acute and chronic post-concussion symptoms to help them in evaluating and treating patients by using a patient-centered approach. This activity includes a personal interview featuring a patient who has experienced concussion and is now living with post-concussion syndrome.

RELEASED DATE: June 12, 2022
EXPIRATION DATE: June 30, 2025

This activity is intended to meet the educational needs of fellows and early career physicians who manage adult patients with Pulmonary Arterial Hypertension (PAH).

RELEASED DATE: August 21, 2024
EXPIRATION DATE: August 21, 2025

This educational enduring activity is designed to meet the educational needs of healthcare providers who have a role in treating patients with nontuberculous mycobacterial lung disease (NTM-LD), including strategies for overcoming treatment resistance. This activity is designed to increase healthcare providers’ knowledge of treatment approaches and opportunities to implement NTM-LD treatment guidelines in real-world clinical practice. In addition, this program will use a multidisciplinary team (MDT) of specialists and incorporate patient shared decision making (SDM) policies to provide holistic, patient-centered care.

RELEASED DATE: October 25, 2024
EXPIRATION DATE: October 25, 2025

This enduring presentation is designed to assist members of multidisciplinary oncology care teams at VA hospitals, including oncologists, pathologists, and nurse practitioners, so that they may better understand and implement molecular diagnostic approaches and biomarker-driven testing strategies in their veteran patients with cancer. The program places special emphasis on the role of NTRK gene fusion and TRK fusion testing, the implications of TRK pathway aberrations in cancer pathogenesis, and clinical trial data surrounding TRK inhibitors.

RELEASED DATE: November 25, 2024
EXPIRATION DATE: November 25, 2025